Intelence Related Published Studies
Well-designed clinical trials related to Intelence (Etravirine)
Cost-effectiveness of combination therapy with etravirine in
treatment-experienced adults with HIV-1 infection. [2012]
Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. [2011.07]
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. [2011.05]
A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. [2011.01.28]
A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. [2011.01.02]
A randomized crossover study to compare efavirenz and etravirine treatment. [2011.01.02]
Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials. [2010.11]
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. [2010.11]
Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials. [2010.11]
Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2. [2010.07]
Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300. [2010.06]
Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials. [2010.01]
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. [2010]
Effects of etravirine versus placebo on health-related quality of life in
treatment-experienced HIV patients as measured by the functional assessment of
human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials. [2010]
[Role of etravirine in combination antiretroviral therapy] [2009.12]
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. [2009.11.13]
Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers. [2009.10.01]
Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. [2009.04]
Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. [2008.11]
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection. [2008.10.01]
Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. [2008.09.14]
Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers. [2008.06]
Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance? [2008.05.11]
Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. [2008]
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. [2007.07.07]
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. [2007.07.07]
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. [2007.03.30]
Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial. [2007.03]
Well-designed clinical trials possibly related to Intelence (Etravirine)
High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. [2011.06.10]
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. [2007]
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. [2003.12.05]
A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. [2003.11.21]
Other research related to Intelence (Etravirine)
Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. [2011.11.28]
Cost-effectiveness of Combination Therapy With Etravirine in Treatment-Experienced Adults With HIV-1 Infection in Canada. [2011.11.14]
Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients. [2011.08]
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients. [2011.07]
Endothelial, inflammatory, coagulation, metabolic effects and safety of etravirine in HIV-uninfected volunteers. [2011.06]
Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. [2011.05.21]
Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance. [2011.05.15]
Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples. [2011.05]
Interaction potential of etravirine with drug transporters assessed in vitro. [2011.03]
Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. [2011.03]
Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. [2011.01.01]
A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s). [2010.11]
Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients. [2010.09.29]
Characterization of Genotypic and Phenotypic Changes in HIV-1-Infected Patients with Virologic Failure on an Etravirine-Containing Regimen in the DUET-1 and DUET-2 Clinical Studies. [2010.09.20]
Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials. [2010.08.27]
Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data. [2010.06]
Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. [2010.04.01]
Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. [2010.04]
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. [2010.04]
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. [2010.02.20]
Profile of etravirine for the treatment of HIV infection. [2010.02.02]
Etravirine: A novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection. [2010.02.01]
Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults. [2010.02]
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naive patients infected with non-B HIV-1 subtypes. [2010.02]
Simplification of antiretroviral therapy with etravirine. [2010.01]
Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. [2010]
Etravirine: clinical review of a treatment option for HIV type-1-infected
patients with non-nucleoside reverse transcriptase inhibitor resistance. [2010]
Etravirine in combination with darunavir/ritonavir and optimized background
regimen results in suppression of HIV replication in treatment-experienced
patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and
safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week
analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300. [2010]
[Etravirine in special populations] [2009.12]
[Etravirine: genetic barrier and resistance development] [2009.12]
[Etravirine drug interactions] [2009.12]
[Safety and tolerability of etravirine] [2009.12]
[Etravirine in first-line therapy] [2009.12]
[Etravirine in highly treatment-experienced patients] [2009.12]
[Chemical characteristics, mechanism of action and antiviral activity of etravirine] [2009.12]
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. [2009.11.01]
Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine). [2009.11]
Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). [2009.09.01]
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. [2009.08.25]
Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers. [2009.07.17]
Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone. [2009.07]
Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. [2009.04.15]
Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms. [2009.04]
Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection. [2009.03.17]
Efficacy of etravirine for treatment of acute HIV meningoencephalitis. [2009.03.15]
Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. [2009.03]
Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. [2009.03]
Raltegravir and etravirine are active against HIV type 1 group O. [2009.02]
Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial. [2009.01.28]
Clinical pharmacokinetics and pharmacodynamics of etravirine. [2009]
Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors. [2008.12]
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. [2008.12]
Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. [2008.11.12]
Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. [2008.10]
A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. [2008.10]
Shifting paradigms: the resistance profile of etravirine. [2008.10]
Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting. [2008.09]
Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine. [2008.08]
A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-volunteers. [2008.05.19]
Etravirine. [2008.01]
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. [2008]
Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. [2008]
Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression. [2008]
Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1. [2008]
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. [2007.07.11]
Other possibly related research studies
Complexity of interactions between voriconazole and antiretroviral agents. [2008.05]
Gateways to clinical trials. [2008.01]
Hemorrhagic cardiomyopathy in male mice treated with an NNRTI: the role of vitamin K. [2008]
Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. [2008.03]
|
